NBIX research · 13F holders by reporting quarter
Neurocrine Biosciences Inc (NBIX): 13F holders, 2025Q4
The largest share positions in NBIX that the managers Kresmion follows reported on Form 13F for 2025Q4, as filed. The current quarter, the company's SEC filings and its recent events are on the NBIX research page.
NBIX positions held by the managers we follow (2025Q4)
What the managers we follow bought and sold in Q2 2026
| Manager / security | Market value | % of reported value | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 64125C109 · 2025Q4 | $317.5M | 0.49% | -7.4% |
| TWO SIGMA INVESTMENTS, LP FundCUSIP 64125C109 · 2025Q4 | $139.7M | 0.21% | +183.3% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 64125C109 · 2025Q4 | $62.8M | 0.05% | +773.5% |
| Bridgewater Associates, LP FundCUSIP 64125C109 · 2025Q4 | $21.3M | 0.08% | +551.1% |
| CITADEL ADVISORS LLC FundCUSIP 64125C109 · 2025Q4 | $11.3M | 0.01% | n/a |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.